Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Sana Biotechnology, Inc. (NASDAQ:SANA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Great. Thanks, everyone, for being here.
Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript
Sana Biotechnology, Inc. (NASDAQ:SANA ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President Thank you for being here. My name is Sam Semenkow, I'm one of the Biotech analysts here at Citi.
Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued
Sana's allogeneic HIP technology achieved a first in T1D, showing insulin production and immune evasion without immunosuppression, but scalability remains unproven. Despite promising early data, Sana faces significant risks: cash burn, a small recent raise, key executive departures, and a long path to commercialization. Management's experience and the disruptive potential of HIP technology support my continued Buy rating, but I advise caution due to high risk and lack of near-term catalysts.
Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human study using UP421 as a HIP-modified primary islet cell therapy to treat patients with Type 1 Diabetes established increase circulating C-peptide biomarker and without need of immunosuppressive therapy. An IND filing to initiate a phase 1 study using SC451 for the treatment of patients with Type 1 Diabetes, expected in 2026.
Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421
SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
Sana Biotechnology skyrockets 200% on positive diabetes study data
Sana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's UP421 allogeneic primary islet cell therapy into a type 1 diabetes patient, a statement said.
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense.
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression.
Citi keeps $15 target on Sana, says data 'potentially transformative'
Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the analyst tells investors in a research note. The data demonstrate a "major scientific advance" for type 1 diabetes patients as it suggests Sana's hypoimmune edits permit islet cell transplant survival in the absence of immunosuppression, the analyst tells investors in a research note. Citi believes the implications extend beyond type 1 diabetes and islet cells though, and could potentially be applied broadly within the allogeneic field. The firm anticipates the stock could continue to appreciate after the open today and keeps a Buy rating on the name with a $15 price target. Sana in premarket trading is up 274%, or $4.52, to $6.17.
H.C. Wainwright ups Sana target after 'best case scenario' data
H.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based on today's data and for SC291 for autoimmune diseases to 20% from 15% based on the Phase 1 data and progress from competitor allogeneic CAR-T programs in the space. The first patient dosed with hypoimmune islet cells showcased cell survive and function without immunosuppression, the analyst tells investors in a research note. H.C. Wainwright says the patient met all the primary and secondary trial endpoints. It views the data as the "best case scenario" for the initial type 1 diabetes update.
